This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Ms. Mitrany has been serving as SVP Head of Teva’s corporate economic department since 2012, with global responsibility for Teva’s business planning and analysis.
Prior to that Ms. Mitrany held various positions in Teva, including CFO of specialty R&D, and CFO and FP&A of the global branded business.
Ms. Mitrany joined Teva in 1995 as a financial analyst of Copaxone – the first innovative product of Teva for the treatment of multiple sclerosis.
Ms. Mitrany received her BA in Economics and MBA in Finance, both from Tel-Aviv University.
With over 20 years of experience in finance, M&A and business operations, primarily in the pharmaceutical industries, Ms. Mitrany provides broad and experienced knowledge of the global pharmaceutical business and industry.